MCM
FLGT icon

Moore Capital Management’s Fulgent Genetics FLGT Stock Holding History

Moore Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$992K Buy
48,343
+2,219
+5% +$37.6K 0.01% 496
2026
Q1 		$733K Buy
+46,124
New +$1M 0.01% 394

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Moore Capital Management's FLGT Position: Q2 2026 in Review

Moore Capital Management increased its Fulgent Genetics (FLGT) stake by 4.8% in Q2 2026, buying an estimated $37.6K and bringing the position to 48,343 shares worth $992K. The position accounts for 0.01% of the portfolio, ranked #496.

Moore Capital Management first reported a position in FLGT in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Moore Capital Management held 48,343 shares of Fulgent Genetics worth $992K as of Q2 2026.
  • Moore Capital Management bought 2,219 Fulgent Genetics shares in Q2 2026, an estimated $37.6K.
  • Fulgent Genetics made up 0.01% of Moore Capital Management's portfolio in Q2 2026, its #496 holding.
  • Moore Capital Management first reported a position in Fulgent Genetics in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.